Merck & Co Inc

Merck & Co Inc(MRK)の株式分析

$147.370

+5.600 (+3.80%)終値時点

Loading chart…
高値
148.155
始値
143.100
出来高加重平均価格
146.06
出来高
9.78M
時価総額
—
安値
142.660
売買代金
1.43B
EV/EBITDA(TTM)
62.00

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

www.merck.com

AI分析 of Merck & Co Inc (MRK)

買い

Merck & Co Inc is a good buy right now due to its current price of $145.60 being below the average analyst price target of $165, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +36.78% and a 1-year change of +69.89%, reflecting solid performance. However, the main risk is the significant insider selling, which has increased by 2945.40% over the last month, indicating potential concerns from insiders about the company's future performance.

アナリスト評価(21)

-18.89% 下落余地
買い
11 買い
10 中立
0 売り
現在: 147.37
安値
95.00
平均
119.53
高値
139.00

Citi

2026-10-12

目標株価

$145

中立

BofA

2026-10-09

目標株価

$163

買い

Cantor Fitzgerald

2026-10-08

目標株価

$145

中立

Morgan Stanley

2026-10-07

目標株価

$177

オーバーウェイト

JPMorgan

2026-10-05

目標株価

$165

オーバーウェイト

バリュエーション指標

Merck & Co Inc(MRK)の現在の予想PERは15.29で、5年平均は18.33です。

予想PER

適正
5年平均 P/E
18.33
現在のP/E
15.29
割高
34.10
割安
2.56

予想EV/EBITDA

大幅な割高
5年平均 EV/EBITDA
13.93
現在のEV/EBITDA
62.00
割高
26.77
割安
1.09

予想PSR

割高
5年平均 P/S
4.14
現在のP/S
5.14
割高
4.75
割安
3.52

Alphio AI による MRK の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%MRK

$87.07

シナリオ価格

基

基本

基本 · 50%MRK

$73.78

シナリオ価格

弱

弱気

弱気 · 25%MRK

$65.85

シナリオ価格

MRK を保有するクジラ

C

Corient Private Wealth LP

+ を保有MRK

+52.24%

3か月リターン

T

Turtle Creek Management, LLC

+ を保有MRK

+22.84%

3か月リターン

O

Ofi Invest Asset Management

+ を保有MRK

+16.52%

3か月リターン

H

Howard Capital Management, Inc.

+ を保有MRK

+16.16%

3か月リターン

M

MUFG Securities EMEA plc

+ を保有MRK

+14.83%

3か月リターン

A

ARGA Investment Management, LLC

+ を保有MRK

+13.85%

3か月リターン

イベントタイムライン

2026-10-13 (ET)

07:30:00

Merck & Co. Elects Paul Diaz to Board

2026-10-11 (ET)

15:30:00

Merck Presents One-Year Results of Remigromig for Diabetic Macular Edema

2026-10-07 (ET)

16:30:00

Major Averages Decline After Fed Meeting Minutes Release

12:30:00

Major Averages Broadly Lower as 10-Year Treasury Yield Rises to 5.356%

ニュース

MRK のよくある質問 — Alphio AI が回答

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Merck & Co Inc is a good buy right now due to its current price of $145.60 being below the average analyst price target of $165, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +36.78% and a 1-year change of +69.89%, reflecting solid performance. However, the main risk is the significant insider selling, which has increased by 2945.40% over the last month, indicating potential concerns from insiders about the company's future performance.

21 analysts cover MRK: 11 rate it Buy, 10 Hold and 0 Sell. The average price target is 119.53.

コミュニティ

もっと見る ↗
molten_vortex2026/9/26

Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT

もっと見る
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める